NEUROENDOCRINE TUMOUR OF PANCREAS CANCER Cancer has been one of the leading monsters to put its cold hands over people in today’s time

Cancer has been one of the leading monsters to put its cold hands over people in today’s time. As per the statistics it is estimated that more than 12,000 people in the United States are diagnosed with a neuroendocrine tumour each year. Having said this, there are different statistical data for different types of neuroendocrine tumours. As per my focus area, there have been 1,000 cases diagnosed with the Neuroendocrine tumour of the Pancreas in the United States of America. This is a very rare type of cancer and contributes about 3% to 5% of all the pancreatic cancers. People are usually diagnosed with a pancreatic neuroendocrine tumour between the ages of 30 and 60. However, these types of tumours that are the result of a genetic syndrome tend to occur during childhood or young adulthood.

Let’s dive into the Concept of Cancer and different types of Tumour formation:
Cell division is a normal process in a multicellular organism. Growth and repair of cells take place as a result of cell division (mitosis). Most cells undergo frequent division except liver and brain cells which rarely divide in a mature adult. Sometimes however, cell division becomes very rapid and uncontrolled, leading to cancer.

We Will Write a Custom Essay Specifically
For You For Only $13.90/page!

order now

Cancer is defined as a malignant cellular tumour that, unlike the benign tumour cells, can metastasize and invade the surrounding and distant tissues. Cells which undergo rapid, abnormal and uncontrolled at the cost of remaining cells are called neoplastic cells. The growth resulting from such cells are called neoplastic growths or tumours.
What are tumours?
A swelling of a part of the body, generally without inflammation, caused by an abnormal growth of tissue. There are two types of tumours:
Benign tumour – Abnormal and persistent cell division that remains localized at the spot of origin results in the benign tumours. These tumours stop growing after reaching a certain size and they have a capsule like formation around them. Thus, they are usually not fatal except for brain tumour where, it causes pressure on the vital centre.
Malignant tumour – A malignant tumour is medically defined as Cancer. It can attack neighbouring tissue and organs through blood or lymph system (plays an important role in fighting infection). Such obtrusive malignancies results in the death of the subject suffering. These tumours do not stop growing and become larger in size with time, leading to organ failure and other secondary diseases and death.

What are Neuroendocrine tumours (NETs) ?Neuroendocrine tumours (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous systems. Many are benign, while some are malignant. They most commonly occur in the intestine, where they are often called carcinoid tumours, but they are also found in the pancreas, lungs and the rest of the body. Neuroendocrine tumours despite differing embryological origin, have common phenotypic characters.
Types of neuroendocrine tumours :
There are many types of neuroendocrine tumours : pheochromocytoma, Merkel cell cancer, and neuroendocrine carcinoma. Other types of tumours that begin in hormone-producing cells are pancreatic neuroendocrine tumours, thyroid cancer, adrenal gland tumours, and pituitary gland tumours.

Looking into the biology of the pancreas :The pancreas is a pear-shaped gland located in the abdomen between the stomach and the spine. It is about 6 inches long. It is made up of 2 major components:
Exocrine component: This segment is comprised of ducts with little sacs called acini toward the end. It produces specific proteins known as enzymes that act as the catalysts that are discharged into the small intestine to enable the body to process and break down food components, such as fats.

Endocrine component: This region of the pancreas is comprised of specific cells grouped together in islands inside the organ, called islets of Langerhans. These cells produce hormones, such as insulin. Insulin is responsible in maintaining the blood sugar level.

Panceratic neuroendocrine tumour :It is not so common for a tumour to develop in the islets of Langerhans, the endocrine component. This tumour is referred to as pancreatic neuroendocrine tumours or the islets of Langerhans tumours. A pancreatic neuroendocrine tumour is classified as either benign or cancerous and as either functioning or non-functioning. The cells of a functional pancreatic neuroendocrine tumour produce hormones that cause specific symptoms. A non-functioning pancreatic neuroendocrine tumour does not cause hormonal symptoms. Most pancreatic neuroendocrine tumours are non-functioning; thus, these tumours are usually diagnosed at a more advanced stage.
Symptoms of Pancreatic Neuroendocrine Tumour :Pancreas produce hormones to regulate the blood sugar levels, stomach acid production, rate of food absorption and amount of water in the intestines. Functional pancreatic neuroendocrine tumours may cause the pancreas to overproduce certain hormones, resulting in a number of symptoms.

The following are the symptoms specific to functional pancreatic neuroendocrine tumours:
Gastrinoma (Zollinger-Ellison Syndrome)
Gastrin produce Gastrinoma.

The symptoms of the production of gastrinoma are:
Acid reflux, burning and abdominal pain, diarrhoea, excess fat in the stools and weight loss.

Glucagon produce Glucaganoma.

The symptoms of the production of Glucaganoma are:
High blood sugar, severe swelling or irritation of the skin, mouth sores, anaemia and weight loss.

Insulin produces Insulinoma. It is responsible for maintaining the blood sugar levelin the body. The symptoms of the production of Insulinoma are:
Low blood sugar causing heart palpitation, shakiness, perspiration, confusion and seizures.
SomatostatinomaSomatostatin produces Somatostatinoma. Somatostatin is a growth hormone; thus, this hormone suppresses production of a variety of other hormones,
The symptoms of this condition of the pancreas are unknown and non-specific. They include diabetes, gallstones, weight loss, diarrhoea, excess fat in the stool, nausea and vomiting.

Vasoactive Intestinal Peptide Releasing Tumour
(VIPoma) is produced by the Vasoactive Intestinal Peptide (VIP), which are predominantly found in the gut and the pancreas. It is responsible pointing the neurons through postsynaptic target to regulate circadian rhythm.

(Verner-Morrison Syndrome)
The symptoms for the same are: sever watery diarrhoea, which can lead to low blood potassium levels causing muscle weakness, fatigue and nausea.

{Symptoms of Pancreatic Neuroendocrine Tumours – Pancreatic Cancer Action Network/. (2018). Pancreatic Cancer Action Network. Retrieved 13 October 2018, from is the Pancreatic Neuroendocrine Tumour determine?
The staging system of the Pancreatic NETs often used in the American Joint Committee on Cancer (AJCC) is the TNM system, which is based on 3 important snippets of data:
The size and degree of the primary tumour (T): How vast is the tumour? Has it developed into adjacent structures or organs?
The spread to adjacent lymph hubs (N): Has the malignancy spread to close-by lymph hubs?
The spread (metastasis) to removed destinations (M): Has the growth spread too far off organs? It is mostly determined to be spread into the liver.

Pancreatic NETs are typically given the clinical stages based on:
Physical exams
Imaging test such as x-rays, magnetic fields, sound waves, or radioactive substances to create pictures of the inside of your body
CT scans – Multiphase CT scan or a Pancreatic protocol CT scan
Ultrasounds – Endoscopic ultrasound (EUS)
Magnetic Resonance Imaging – MR cholangiopancreatography (MRCP), MR angiography (MRA)
Positron emission tomography (PET) scan
Somatostatin receptor scintigraphy (SRS)
Blood tests for pancreatic neuroendocrine tumours :Liver function tests
Tumour markers – CA 19-9, Carcinoembryonic antigen (CEA)
Carcinoid Tumours
Hormones made by different types of NET cells, such as insulin, gastrin, glucagon, somatostatin, pancreatic polypeptide, and VIP (vasoactive intestinal peptide)
Chromogranin A (CgA)
Glucose and C-peptide (for insulinomas)
AJCC stage Stage grouping Stage disriptionT1
M0 The tumour is less than 2 centimeters (cm) across and is still just in the pancreas (T1).
The cancer has not spread to nearby lymph nodes (N0)
Distant parts of the body (M0).

M0 The tumour is at least 2 cm across but no more than 4 cm across, and it is still just in the pancreas (T2).
The cancer has not spread to nearby lymph nodes (N0)
Distant parts of the body (M0).

The tumour is more than 4 cm across and is still just in the pancreas, OR the tumour has grown into the duodenum (the first part of the small intestine) or the common bile duct (T3).
The cancer has not spread to nearby lymph nodes (N0)
Distant parts of the body (M0).

Any T
M0 The tumour has grown into nearby organs (such as the stomach, spleen, colon, or adrenal gland) or it has grown into nearby large blood vessels (T4).
The cancer has not spread to nearby lymph nodes (N0)
Distant parts of the body (M0).

The tumour can be any size and might or might not have grown outside of the pancreas (any T).

It has spread to nearby lymph nodes (N1),
but not too distant parts of the body (M0).

Any T
Any N
M1 The tumour can be any size and might or might not have grown outside of the pancreas (any T).
It might or might not have spread to nearby lymph nodes (any N). The cancer has spread to distant parts of the body (M1).

{Pancreatic Neuroendocrine Tumour Stages – Pancreatic Neuroendocrine Tumour Stages. (2018). Retrieved 13 October 2018, from}
* The following additional categories are not listed in the table above:
TX: The main tumour cannot be assessed due to lack of information.
T0: There is no evidence of a main tumour.

NX: Nearby lymph nodes cannot be assessed due to lack of information.

Tests for Pancreatic Cancer.

Pancreatic Neuroendocrine Tumour Stages.

Pancreatic Neuroendocrine Tumour | Genetic and Rare Diseases Information Centre (GARD) – a NCATS Program.

Worldwide Cancer Data.” World Cancer Research Fund, August 6, 2018.

Svorcan, P., Djordjevic, J. and Maksimovic, B.

Svorcan, P., Djordjevic, J., & Maksimovic, B. (2011). A Rare Gastric Carcinoma- Neuroendocrine Tumours. Management of Gastric Cancer. doi:10.5772/17554


I'm Delia!

Would you like to get a custom essay? How about receiving a customized one?

Check it out